|
|
|
|
Science Sparks @ ACTREC
|
 11th December 2023 |
Vol. No. 12 ; Issue No. 608 |
|
|
Publications
|
|
1. Colaco V, Goswami N, Goel VK, Srivastava SK, Lalrohlua P, Senthil Kumar N, Borah P, Baruah R, Varma AK (2023). In silico and structure-based evaluation of deleterious mutations identified in human Chk1, Chk2, and Wee1 protein kinase. Journal of Cellular Biochemistry.
2. Ghantasala S, Bhat A, Epari S, Moiyadi A, Srivastava S. High-grade gliomas from subventricular zone: Proteomic drivers of aggressiveness using fluorescence-guided multiple sampling. OMICS: A Journal of Integrative Biology (2023).
3. Vahabi M, Shahil-Feroz A, Lofters A, Wong JP, Prakash V, Pimple S, Anand K, Mishra G (2023). Surviving the Storm: The Impact of COVID-19 on Cervical Cancer Screening in Low- and Middle-Income Countries. Healthcare. 11(23): 3079.
4. Huck C, Achard V, Maitre P, Murthy V, Zilli T. Stereotactic body radiation therapy for prostate cancer after surgical treatment of prostatic obstruction: Impact on urinary morbidity and mitigation strategies. Clinical and Translational Radiation Oncology.
|
|
|
|
|
Interesting Reads
|
|
Taifour T, Attalla SS, Zuo D, Gu Y, Sanguin-Gendreau V, Proud H, Solymoss E, Bui T, Kuasne H, Papavasiliou V, Lee CG, Kamle S, Siegel PM, Elias JA, Park M, Muller WJ (2023). The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer. Immunity.
|
|
|
Video of the Week
|
|
| Gut and Intratumoral Microbiome: Diagnostic and Therapeutic Implications |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 2001, Results of a clinical trial showed that the drug imatinib mesylate, which targets a unique protein produced by the Philadelphia chromosome, is effective against chronic myelogenous leukemia (CML).
|
|
|
|
|
|
2019 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
